HBM Healthcare Investments

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Cartesian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in the United States that specializes in developing innovative cell and gene immunotherapies for the treatment of cancer and autoimmune diseases. The company focuses on chimeric antigen receptor therapies to address multiple myeloma and other forms of cancer. Cartesian Therapeutics employs its proprietary ImmTOR immune tolerance platform, which aims to foster antigen-specific immunity while reducing unwanted immune responses. This approach utilizes a manufacturing platform to introduce mRNA molecules into cells, enhancing their functionality without the risk of integration into the cell's genetic material, as mRNA naturally degrades over time.

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing curative treatments for infectious diseases, with an initial focus on chronic Hepatitis B. This disease remains prevalent worldwide and has significant unmet medical needs. The company is pursuing two innovative approaches: fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. These therapies aim to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially achieving a functional cure for patients.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

Shape Memory Medical Inc is a medical device company located in Santa Clara, California, focused on creating innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. The company specializes in utilizing Shape Memory Polymer (SMP) technology, which was originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical is notable for being the first to introduce an FDA-cleared medical device incorporating SMP technology specifically for the vascular market, thereby enhancing the capabilities of physicians in patient care. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Vicore Pharma Holding is a clinical-stage pharmaceutical company that specializes in developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company is advancing its lead drug candidate, C21, a small molecule angiotensin II type 2 receptor agonist, which is currently in phase 2a clinical development for IPF and has received orphan drug designation in both the EU and the US. In addition to C21, Vicore is exploring pre-clinical applications of the drug in other rare diseases associated with the AT2 receptor. The company is also developing Almee, a digital therapeutic that utilizes cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. Headquartered in Astra Zeneca’s Bioventurehub in Mölndal, Vicore Pharma aims to establish a comprehensive portfolio targeting respiratory diseases.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Farmalisto is an online pharmacy that serves as a bridge between healthcare providers and patients in Colombia and Mexico. Founded in 2013 and based in Bogotá and Mexico City, the company specializes in offering a wide array of products, including pharmaceuticals and health-related items such as haircare, dental products, and baby hygiene necessities. In addition to product sales, Farmalisto enhances the pharmaceutical landscape by providing logistics, marketing, and disease management services tailored for pharmaceutical companies. Its platform not only facilitates easy access to medicines, particularly for chronic and complex conditions, but also includes home assistance and patient support programs, ensuring that patients can receive necessary care from the comfort of their homes or offices.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Mahzi Therapeutics is a biotechnology company established in 2020 and based in San Mateo, California. The company specializes in developing therapeutics for underserved rare genetic neurodevelopmental disorders. By focusing on biopharmaceutical research, development, and manufacturing, Mahzi Therapeutics aims to address the treatment gaps in rare diseases, ultimately enhancing the healthcare industry's ability to provide effective solutions for these conditions.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Valcare, Inc., established in 2012 and headquartered in Irvine, California, specializes in the design and development of medical devices and accessories for minimally invasive treatment of heart valve disease. The company's core technology is a transcatheter platform that functions as a docking station for replacement prostheses and a tool for mitral annulus repair, aiming to improve treatment options and accelerate recovery for patients with mitral and tricuspid regurgitation.

Shape Memory Medical Inc is a medical device company located in Santa Clara, California, focused on creating innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. The company specializes in utilizing Shape Memory Polymer (SMP) technology, which was originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical is notable for being the first to introduce an FDA-cleared medical device incorporating SMP technology specifically for the vascular market, thereby enhancing the capabilities of physicians in patient care. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Farmalisto is an online pharmacy that serves as a bridge between healthcare providers and patients in Colombia and Mexico. Founded in 2013 and based in Bogotá and Mexico City, the company specializes in offering a wide array of products, including pharmaceuticals and health-related items such as haircare, dental products, and baby hygiene necessities. In addition to product sales, Farmalisto enhances the pharmaceutical landscape by providing logistics, marketing, and disease management services tailored for pharmaceutical companies. Its platform not only facilitates easy access to medicines, particularly for chronic and complex conditions, but also includes home assistance and patient support programs, ensuring that patients can receive necessary care from the comfort of their homes or offices.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

1000Farmacie is the leading pharmacy marketplace in Italy, operating an online shopping platform that connects consumers with a network of independent pharmacies. The company provides a wide range of pharmaceutical products, allowing users to purchase healthcare items at competitive prices. With a focus on convenience, 1000Farmacie ensures same-day delivery of products to specified locations, helping customers save time and money while accessing essential healthcare products from authorized pharmacies.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

SK Biopharmaceuticals Co., Ltd., founded in 2011 and headquartered in Seongnam, South Korea, focuses on the research, discovery, and development of pharmaceuticals targeting central nervous system disorders. The company is advancing several key products, including Cenobamate for epilepsy, Solriamfetol for excessive daytime sleepiness, and Carisbamate for Lennox-Gastaut syndrome, with various candidates in different stages of clinical trials. Other investigational drugs include Relenopride for rare neurological diseases and compounds targeting attention deficit/hyperactivity disorder, schizophrenia, bipolar disorder, and epilepsy. SK Biopharmaceuticals aims to establish itself as a leading specialty pharmaceutical company by developing innovative treatments and providing high-quality pharmaceutical manufacturing services.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

Ignis Therapeutics is a life science company focused on developing innovative therapies for central nervous system (CNS) conditions. Committed to advancing treatment paradigms, the company aims to transform the approach to treating CNS disorders. Ignis Therapeutics is dedicated to creating products that significantly enhance the quality of life for patients while offering additional therapeutic options for healthcare providers. Through its emphasis on self-discovery and strategic development, Ignis Therapeutics seeks to address unmet medical needs in the CNS space.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases. Using modern machine learning techniques, Odyssey is transforming the landscape of autoimmune treatments. Odyssey Therapeutics was founded in 2018 and is based in San Francisco, California.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

Mahzi Therapeutics is a biotechnology company established in 2020 and based in San Mateo, California. The company specializes in developing therapeutics for underserved rare genetic neurodevelopmental disorders. By focusing on biopharmaceutical research, development, and manufacturing, Mahzi Therapeutics aims to address the treatment gaps in rare diseases, ultimately enhancing the healthcare industry's ability to provide effective solutions for these conditions.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.

Cardialen, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in developing innovative therapies for heart arrhythmias, particularly atrial fibrillation. Founded in 2008, the company focuses on creating implantable devices that provide low-energy, pain-free cardioversion therapies to restore normal heart rhythm. These devices utilize a proprietary technology that delivers a sequential series of low-voltage pulses to effectively address atrial fibrillation and other related conditions, such as rapid ventricular tachycardia and ventricular fibrillation, while minimizing patient discomfort and protecting heart tissue from damage. By targeting significant unmet medical needs, Cardialen aims to improve the quality of life for individuals suffering from these heart conditions.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Shape Memory Medical Inc is a medical device company located in Santa Clara, California, focused on creating innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. The company specializes in utilizing Shape Memory Polymer (SMP) technology, which was originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical is notable for being the first to introduce an FDA-cleared medical device incorporating SMP technology specifically for the vascular market, thereby enhancing the capabilities of physicians in patient care. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Valcare, Inc., established in 2012 and headquartered in Irvine, California, specializes in the design and development of medical devices and accessories for minimally invasive treatment of heart valve disease. The company's core technology is a transcatheter platform that functions as a docking station for replacement prostheses and a tool for mitral annulus repair, aiming to improve treatment options and accelerate recovery for patients with mitral and tricuspid regurgitation.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Visen Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for endocrine diseases, addressing significant unmet medical needs in China. The company emphasizes patient-centric care, aiming to provide first-in-class or best-in-class treatments for both common and rare endocrine disorders affecting adults and children. With a team of experienced professionals from multinational pharmaceutical backgrounds, Visen leverages advanced technologies and resources to enhance its operations. The company has established a strong presence in the Chinese market, with offices in Shanghai, Beijing, Hong Kong, and Taipei, as well as a research and manufacturing site in Suzhou. This strategic setup aims to accelerate the availability of advanced treatment solutions for endocrine patients in China.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Instil Bio, Inc., established in 2018 and headquartered in Dallas, Texas, specializes in developing and commercializing tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company's primary product is TIL, which involves harvesting a patient's own T cells from their tumor, expanding them, and reinfusing them back into the patient to target and destroy cancer cells. Instil Bio is advancing its proprietary manufacturing expertise and technology into clinical trials, including planned registrational studies for its lead candidate and first-in-human trials for next-generation engineered TIL therapies. Additionally, the company is developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform.

Farmalisto is an online pharmacy that serves as a bridge between healthcare providers and patients in Colombia and Mexico. Founded in 2013 and based in Bogotá and Mexico City, the company specializes in offering a wide array of products, including pharmaceuticals and health-related items such as haircare, dental products, and baby hygiene necessities. In addition to product sales, Farmalisto enhances the pharmaceutical landscape by providing logistics, marketing, and disease management services tailored for pharmaceutical companies. Its platform not only facilitates easy access to medicines, particularly for chronic and complex conditions, but also includes home assistance and patient support programs, ensuring that patients can receive necessary care from the comfort of their homes or offices.

Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Everlife Asia is a buy-and-build platform focused on delivering comprehensive solutions to the healthcare and research sectors. The company operates a group of companies that invest in manufacturers and distributors across Asia, targeting key segments such as in-vitro diagnostics, medical diagnostics, critical care equipment, implants, and consumables. This strategic approach allows Everlife Asia to facilitate access to the fragmented markets within the region, enhancing the efficiency and effectiveness of healthcare delivery.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.

Longboard Pharmaceuticals, Inc., established in 2020 and headquartered in San Diego, California, is engaged in developing optimized medicines targeting neurological diseases. The company focuses on improving pharmacology and pharmacokinetics to create novel treatments for rare conditions. Its pipeline includes LP352, a next-generation 5-HT2C agonist being evaluated for developmental and epileptic encephalopathies; LP143, a centrally acting CB2 receptor full agonist explored for potential treatment of neurological disorders like ALS and PD; and LP659, a highly selective S1P receptor modulator targeting multiple CNS neuroinflammatory disorders. Longboard operates as a subsidiary of Arena Pharmaceuticals, Inc., aiming to deliver these medicines to patients in need.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

BioShin Limited is a clinical-stage biopharmaceutical company focused on developing innovative medicines for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018 and based in Pudong, China, BioShin operates as a wholly owned subsidiary of Biohaven Pharmaceutical Holding Company Ltd. The company is engaged in developing late-stage product candidates and offers clinical trial platforms that explore various therapeutic approaches, including calcitonin gene-related peptide receptor antagonism for migraine relief, glutamate modulation for Alzheimer’s disease and anxiety disorders, and myeloperoxidase inhibition targeting inflammation and neurodegeneration. By addressing significant unmet medical needs in neurological care, BioShin aims to make a substantial impact in the Asia-Pacific market.

Galecto is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to address severe diseases, particularly fibrosis and cancer. Established in 2011, Galecto builds on over a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company's lead product candidate, GB0139, is an inhaled galectin-3 inhibitor specifically designed for treating severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. Additionally, Galecto is advancing GB1211, an oral selective galectin-3 inhibitor aimed at addressing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto leverages its unique therapeutic platform to target the underlying biological processes associated with fibrosis and related diseases.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

Sublimity Therapeutics is a specialty pharmaceutical company focused on developing innovative therapies for gastrointestinal and immunological diseases. Headquartered in Dublin, Ireland, with an additional office in Solana Beach, California, the company aims to address unmet clinical needs through its proprietary oral drug delivery technology. This technology enhances the bioavailability of difficult-to-formulate drugs, allowing for effective systemic or localized delivery within the gastrointestinal tract. Sublimity Therapeutics' product portfolio includes treatments for conditions such as ulcerative colitis, Crohn’s disease, graft versus host disease, and transplant rejection, as well as SmPill formulations for various gastrointestinal disorders. The company's lead product is STI-0529, specifically designed for moderate to severe ulcerative colitis. Founded in 2000 and formerly known as Sigmoid Pharma, Sublimity Therapeutics is committed to advancing oral pharmaceutical formulation technologies to improve patient outcomes in its targeted therapeutic areas.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Everest Medicines Limited is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2017. The company is focused on licensing, developing, and commercializing innovative therapies aimed at addressing significant unmet medical needs primarily in Greater China and other Asia Pacific markets. Its portfolio includes eight clinical-stage drug candidates targeting various conditions, including oncology, immunology, cardio-renal disease, and infectious diseases. By integrating discovery, clinical development, commercialization, and manufacturing processes, Everest Medicines seeks to deliver potentially transformative pharmaceutical therapies that improve patient outcomes. The company aims to partner with leading global pharmaceutical firms to bring its products to market, leveraging its team's expertise in clinical development, regulatory affairs, and operations.

Guangdong Jianke Pharmaceutical Co., Ltd. operates a network of nine pharmacy stores and an online retail platform in China. Established in 2006 and based in Dongguan, the company offers a diverse range of products, including medications for hepatobiliary, dermatology, pediatric, and urology conditions, as well as treatments for digestive, nervous, and respiratory systems. Jianke also provides female health medication, health care products, medical instruments, and beauty care items. The company focuses on addressing the needs of patients with chronic diseases through its online chronic disease management services, which complement its pharmacy offerings. Its primary revenue stream comes from online retail pharmacy services, supplemented by comprehensive medical services and tailored marketing solutions.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Shape Memory Medical Inc is a medical device company located in Santa Clara, California, focused on creating innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. The company specializes in utilizing Shape Memory Polymer (SMP) technology, which was originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical is notable for being the first to introduce an FDA-cleared medical device incorporating SMP technology specifically for the vascular market, thereby enhancing the capabilities of physicians in patient care. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Farmalisto is an online pharmacy that serves as a bridge between healthcare providers and patients in Colombia and Mexico. Founded in 2013 and based in Bogotá and Mexico City, the company specializes in offering a wide array of products, including pharmaceuticals and health-related items such as haircare, dental products, and baby hygiene necessities. In addition to product sales, Farmalisto enhances the pharmaceutical landscape by providing logistics, marketing, and disease management services tailored for pharmaceutical companies. Its platform not only facilitates easy access to medicines, particularly for chronic and complex conditions, but also includes home assistance and patient support programs, ensuring that patients can receive necessary care from the comfort of their homes or offices.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.